Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.
Evoke Pharma Inc (EVOK) is a biotechnology innovator focused on advancing treatments for gastrointestinal disorders, notably through its FDA-approved GIMOTI® nasal spray for diabetic gastroparesis. This page provides investors and healthcare professionals with essential updates on the company's strategic initiatives, clinical developments, and market progress.
Access real-time announcements including regulatory milestones, financial results, and partnership agreements that shape Evoke's position in specialty pharmaceuticals. Our curated news feed covers critical updates such as prescription adoption trends, distribution network expansions, and intellectual property developments related to nasal drug delivery technologies.
Key areas of coverage include GIMOTI commercialization progress, pharmacy network partnerships, and operational efficiency initiatives. Bookmark this page to stay informed about Evoke Pharma's advancements in addressing unmet needs in gastrointestinal care through its non-oral therapeutic solutions.
Evoke (former NASDAQ: EVOK) and QOL Medical announced that QOL-EOS Merger Sub's tender offer to acquire all outstanding Evoke shares for $11.00 per share in cash expired at 11:59 p.m. ET on December 15, 2025 and was not extended.
Broadridge, the depositary, reported approximately 1,164,862 shares were validly tendered and not withdrawn, representing about 67.63% of outstanding shares at expiration. Following the offer, Merger Sub merged with and into Evoke, converting all non-tendered shares into the right to receive the $11.00 cash consideration (subject to appraisal rights).
As a result, Evoke became a wholly owned subsidiary of QOL Medical, Evoke common shares ceased trading on Nasdaq before the open on December 17, 2025, and the company intends to promptly delist and deregister the shares under the Securities Exchange Act.
Evoke Pharma (NASDAQ: EVOK) reported Q3 2025 results and a proposed acquisition by QOL Medical at $11.00 per share. Q3 net product sales were $4.3M, up 61% YoY, bringing year-to-date sales to $11.1M (+60% YoY). The company received a new U.S. patent for GIMOTI extending expected exclusivity to November 2038 and expanded pharmacy access via Omnicell and Brentwood Pharmacy. Q3 net loss was ~$1.2M (−$0.45/share); SG&A rose to $5.3M. Cash and equivalents were $11.6M, which management says funds operations into Q4 2026. The merger is expected to close in Q4 2025, subject to tender conditions.
Evoke Pharma (NASDAQ: EVOK) agreed to be acquired by QOL Medical for $11.00 per share in cash, a 139.7% premium to Evoke's November 3, 2025 closing price. The boards of both companies approved the transaction, which will be effected via a tender offer and is expected to close in the fourth quarter of 2025. QOL Medical said it will finance the deal with cash on hand and the transaction is not subject to a financing condition.
The announcement highlights Evoke’s commercial product GIMOTI (metoclopramide) nasal spray, described as the first and only FDA-approved nasal spray for acute and recurrent diabetic gastroparesis in adults. Upon successful tender, a QOL subsidiary will merge into Evoke and any remaining shares will be cancelled and converted into the same cash price per share.
Evoke Pharma (NASDAQ: EVOK) has announced significant expansion of access to its GIMOTI® nasal spray through new strategic partnerships. The company has secured relationships with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy, which will substantially increase GIMOTI's availability through specialty pharmacy networks.
The Omnicell partnership will facilitate GIMOTI distribution to major gastroenterology organizations, including Gastro Health (150 locations across 7 states) and OneGI (200+ gastroenterologists across multiple states). These partnerships are expected to nearly double the number of specialty pharmacies with access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis.
Evoke Pharma (NASDAQ: EVOK) has announced the listing of a new patent (U.S. Patent No. 12,377,064) for GIMOTI® (metoclopramide) nasal spray in the FDA's Orange Book. The patent covers the use of GIMOTI® in treating patients with moderate to severe gastroparesis symptoms.
The newly listed patent extends protection until November 17, 2038, approximately eight years beyond their previous patent expiration date of May 15, 2030. This strategic move strengthens Evoke's position in providing non-oral treatment options for diabetic gastroparesis while protecting their innovation investment.
Evoke Pharma (NASDAQ: EVOK) reported strong Q2 2025 financial results, with net product sales surging 47% year-over-year to $3.8 million for their gastroparesis treatment GIMOTI. The company experienced significant growth with a 20% increase in new prescribers and maintained a robust 70% refill rate.
Despite growing sales, Evoke posted a net loss of $1.6 million ($0.62 per share) compared to $1.3 million in Q2 2024. Operating expenses increased to $5.3 million, up from $3.8 million year-over-year. The company maintains a healthy cash position of $12.1 million and expects funding to last through Q3 2026.
Evoke confirmed its full-year 2025 revenue guidance of $16 million, representing a potential 60% increase over 2024, driven by prescription growth and expanded pharmacy access.
Evoke Pharma (NASDAQ: EVOK) has secured a new U.S. patent (No. 12,377,064) for its product GIMOTI®, a nasal spray treatment for gastroparesis. The United States Patent and Trademark Office has extended the patent term to November 2038, providing nearly two additional years of market exclusivity beyond the previous December 2036 expiration.
The patent specifically covers the use of intranasal metoclopramide for patients with moderate to severe gastroparesis symptoms. The company plans to list this patent in the FDA's Orange Book to strengthen GIMOTI's intellectual property position and is pursuing additional related claims through a continuation application.
Evoke Pharma (NASDAQ: EVOK) has received a Notice of Allowance from the USPTO for a patent application covering GIMOTI® (metoclopramide nasal spray) use in moderate to severe gastroparesis patients. The new patent, upon issuance, will extend market exclusivity until December 2036 and will be listed in the FDA's Orange Book.
GIMOTI® is the only FDA-approved, non-oral, self-administered metoclopramide formulation for treating symptoms of acute and recurrent diabetic gastroparesis in adults. The treatment is particularly valuable as gastroparesis can impair the absorption of oral medications. The company has filed an additional U.S. continuation application for further claims related to this patient population.
Evoke Pharma (NASDAQ: EVOK) reported strong Q1 2025 financial results, with net product sales increasing 77% year-over-year to $3.1 million. The company's performance was driven by significant growth in GIMOTI adoption, achieving a 73% increase in fill rate and 44% growth in total prescriber base compared to Q1 2024.
The company reported a net loss of $1.3 million ($0.51 per share), improved from $1.6 million loss in Q1 2024. Operating expenses increased to $4.4 million, up from $3.2 million in the same period last year. With $12.6 million in cash and cash equivalents, Evoke expects to fund operations into Q2 2026.
Evoke maintains its 2025 net product sales guidance of approximately $16 million, representing a 60% increase over 2024. The company also appointed Greg Pyszczymuka to its Board of Directors to strengthen commercial strategy.
Evoke Pharma (NASDAQ: EVOK) has announced the acceptance of a new abstract for presentation at Digestive Disease Week® (DDW) 2025, scheduled for May 3-6, 2025, in San Diego. The research compares tardive dyskinesia (TD) incidence in patients receiving continuous versus intermittent oral metoclopramide treatment.
The analysis, based on real-world data from over 100 million U.S. patients, examines TD incidence rates and timing related to different metoclopramide dosing patterns. The presentation, led by Dr. Pierantonio Russo from EVERSANA Life Sciences, is scheduled for May 5, 2025, from 12:30-1:30 p.m. PT.
CEO Matt D'Onofrio emphasized the importance of understanding metoclopramide's long-term safety profile, particularly for GIMOTI®, the only FDA-approved treatment for diabetic gastroparesis. The abstract will be available through the DDW ePosters site and meeting planner after May 4, 2025. Visitors can learn more at Evoke Pharma's booth #917 during the conference.
FAQ
What is the current stock price of Evoke Pharma (EVOK)?
What is the market cap of Evoke Pharma (EVOK)?
